Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow Reinvestment Rate
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow Reinvestment Rate of 1.06x as of December 2025, reinvesting CN¥587.23 Million (capex CN¥117.78 Million plus investments CN¥-469.45 Million) from operating cash flow of CN¥552.13 Million. See cash generation quality of Tasly Pharmaceutical Group Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tasly Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2001–2025)
Historical reinvestment intensity for Tasly Pharmaceutical Group Co Ltd across 24 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Tasly Pharmaceutical Group Co Ltd.
Annual Cash Flow Reinvestment Rate for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year capital reinvestment analysis for Tasly Pharmaceutical Group Co Ltd. See Tasly Pharmaceutical Group Co Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.52x | CN¥746.36 Million | CN¥1.42 Billion | CN¥381.26 Million | ▲ +31.0% |
| 2024 | 0.40x | CN¥805.29 Million | CN¥2.01 Billion | CN¥564.94 Million | ▼ -62.9% |
| 2023 | 1.08x | CN¥2.78 Billion | CN¥2.58 Billion | CN¥668.82 Million | ▲ +86.2% |
| 2022 | 0.58x | CN¥1.32 Billion | CN¥2.29 Billion | CN¥403.45 Million | ▲ +132.4% |
| 2021 | 0.25x | CN¥698.14 Million | CN¥2.80 Billion | CN¥571.73 Million | ▼ -0.4% |
| 2020 | 0.25x | CN¥448.14 Million | CN¥1.79 Billion | CN¥408.81 Million | ▼ -52.4% |
| 2019 | 0.53x | CN¥882.46 Million | CN¥1.68 Billion | CN¥730.78 Million | ▼ -5.5% |
| 2018 | 0.56x | CN¥830.62 Million | CN¥1.49 Billion | CN¥780.10 Million | ▼ -7.3% |
| 2016 | 0.60x | CN¥691.89 Million | CN¥1.15 Billion | CN¥524.68 Million | ▼ -81.7% |
| 2015 | 3.28x | CN¥1.12 Billion | CN¥340.00 Million | CN¥737.84 Million | ▲ +168.1% |
| 2014 | 1.22x | CN¥754.93 Million | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥663.56 Million | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥390.02 Million | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥422.58 Million | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥166.13 Million | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥116.80 Million | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥114.51 Million | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥201.23 Million | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥255.41 Million | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥296.33 Million | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥369.62 Million | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥328.74 Million | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥126.09 Million | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥119.35 Million | CN¥83.77 Million | CN¥119.35 Million | — |